SYS-CON MEDIA Authors: Adine Deford, Cynthia Dunlop, Harry Trott, Xenia von Wedel, Peter Silva

News Feed Item

Orphan Diseases Partnering Terms and Agreements

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Orphan Diseases Partnering Terms and Agreements

https://www.reportbuyer.com/product/2043441/Orphan-Diseases-Partnering-Terms-and-Agreements.html

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in orphan diseases partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Orphan diseases partnering contract documents
Top orphan diseases deals by value

The Orphan Diseases Partnering Terms and Agreements report provides an understanding and access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter orphan diseases partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors orphan diseases technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 90 links to online copies of actual orphan diseases deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of orphan diseases dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in orphan diseases dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading orphan diseases deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active bigpharma/bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapters 4 and 5 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of orphan diseases deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides comprehensive access to all orphan diseases deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive directory of all orphan diseases partnering deals by specific therapeutic indication announced since 2009. The chapter is organized by specific orphan diseases therapeutic indication. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all orphan diseases partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in orphan diseases partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of orphan diseases technologies and products.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in orphan diseases dealmaking

2.1. Introduction
2.2. Orphan diseases partnering over the years
2.3. Big pharma orphan diseases dealmaking activity
2.4. Big biotech orphan diseases dealmaking activity
2.5. Most active in orphan diseases partnering
2.6. Orphan diseases partnering by deal type
2.7. Orphan diseases partnering by industry sector
2.8. Orphan diseases partnering by stage of development
2.9. Orphan diseases partnering by technology type
2.10. Average deal terms for orphan diseases
2.10.1 Orphan diseases headline values
2.10.2 Orphan diseases upfront payments
2.10.3 Orphan diseases milestone payments
2.10.4 Orphan diseases royalty rates

Chapter 3 - Leading orphan diseases deals

3.1. Introduction
3.2. Top orphan diseases deals by value

Chapter 4 - Big pharma orphan diseases deals

4.1. Introduction
4.2. How to use big pharma partnering deals
4.3. Big pharma orphan diseases partnering company profiles
Dainippon Sumitomo
Galderma
GlaxoSmithKline
Grifols
Kyowa Hakko Kirin
Mitsubishi Tanabe
Novartis
Pfizer
Sanofi
Shire
Shire Human Genetic Therapies
Takeda
Teva

Chapter 5 - Big biotech orphan diseases deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech orphan diseases partnering company profiles
Acorda Therapeutics
Actelion
BioMarin Pharmaceuticals
Grifols
Ipsen
Isis Pharmaceuticals
Swedish Orphan Biovitrum
ViroPharma

Chapter 6 - Orphan diseases partnering contracts directory

6.1. Introduction

6.2. Company A-Z

Aradigm
Arbios Systems
BioMarin Pharmaceutical
Catalyst Pharmaceutical Partners
Cell Therapeutics
Chiesi Farmaceutici
Chroma Therapeutics
Edison Pharmaceuticals
EpiCept
Galderma
GlaxoSmithKline
GlycoMimetics
Grifols
Halozyme Therapeutics
HepaLife
Hyperion Therapeutics
Ikaria
Intellect Neurosciences
Isis Pharmaceuticals
Kyowa Hakko Kirin
Meda
NovaBay Pharmaceuticals
Orphan Therapeutics
Penwest Pharmaceuticals
Pfizer
S*Bio
Saint Louis University
Ucyclyd Pharma
Ultragenyx Pharmaceuticals
UniQure
Viropharma

6.3. By deal type

Asset purchase
Co-development
Collaborative R&D
Co-market
Development
Equity purchase
Licensing
Marketing
Option
Settlement
Supply

6.4. By stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

6.5. By technology type

Assays
Biological compounds
Biomaterials
Cell culture
Enabling technology
Gene therapy
Implant
Oligonucleotide
Peptides
RNA therapeutics
Screening
Small molecules
Stem cells

Chapter 7 - Orphan diseases dealmaking by therapeutic target

7.1. Introduction
7.2. Deals by therapeutic target
Orphan diseases

Appendices

Appendix 1 - Directory of orphan diseases deals by company A-Z 2009- Jan 2014
Appendix 2 - Directory of orphan diseases deals by deal type 2009- Jan 2014
Appendix 3 - Directory of orphan diseases deals by stage of development 2009-Jan 2014
Appendix 4 - Directory of orphan diseases deals by technology type 2009- Jan 2014
Appendix 5 - Partnering resource center

Online partnering
Partnering events
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Therapy Reports

Table of figures

Figure 1: Orphan diseases partnering since 2009
Figure 2: Big pharma - top 50 - Orphan diseases deals 2009 to 2014
Figure 3: Big pharma orphan diseases deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - Orphan diseases deals 2009 to Jan 2014
Figure 5: Big biotech orphan diseases deal frequency - 2009 to 2014
Figure 6: Active orphan diseases dealmaking activity- 2009 to 2014
Figure 7: Orphan diseases partnering by deal type since 2009
Figure 8: Orphan diseases partnering by industry sector since 2009
Figure 9: Orphan diseases partnering by stage of development since 2009
Figure 10: Orphan diseases partnering by technology type since 2009
Figure 11: Orphan diseases deals with a headline value
Figure 12: Orphan diseases deal headline value distribution, US$million - discovery stage
Figure 13: Orphan diseases deal headline value distribution, US$million - preclinical stage
Figure 14: Orphan diseases deal headline value distribution, US$million - phase I stage
Figure 15: Orphan diseases deal headline value distribution, US$million - phase II stage
Figure 16: Orphan diseases deal headline value distribution, US$million - phase III stage
Figure 17: Orphan diseases deal headline value distribution, US$million - regulatory stage
Figure 18: Orphan diseases deal headline value distribution, US$million - marketed stage
Figure 19: Summary median headline value by stage of development, 2009-2014
Figure 20 Orphan diseases deals with upfront payment values
Figure 21: Orphan diseases deal upfront payment distribution, US$million - discovery stage
Figure 22: Orphan diseases deal upfront payment distribution, US$million - preclinical stage
Figure 23: Orphan diseases deal upfront payment distribution, US$million - phase I stage
Figure 24: Orphan diseases deal upfront payment distribution, US$million - phase II stage
Figure 25: Orphan diseases deal upfront payment distribution, US$million - phase III stage
Figure 26: Orphan diseases deal upfront payment distribution, US$million - regulatory stage
Figure 27: Orphan diseases deal upfront payment distribution, US$million - marketed stage
Figure 28: Summary median upfront payments by stage of development, 2009-2014
Figure 29: Orphan diseases deals with milestone payments
Figure 30: Orphan diseases deal milestone distribution, US$million - discovery stage
Figure 31: Orphan diseases deal milestone distribution, US$million - preclinical stage
Figure 32: Orphan diseases deal milestone distribution, US$million - phase I stage
Figure 33: Orphan diseases deal milestone distribution, US$million - phase II stage
Figure 34: Orphan diseases deal milestone distribution, US$million - phase III stage
Figure 35: Orphan diseases deal milestone distribution, US$million - regulatory stage
Figure 36: Orphan diseases deal milestone distribution, US$million - marketed stage
Figure 37: Orphan diseases deals with royalty rates, %
Figure 38: Orphan diseases deal royalty rate distribution, US$million - discovery stage
Figure 39: Orphan diseases deal royalty rate distribution, US$million - preclinical stage
Figure 40: Orphan diseases deal royalty rate distribution, US$million - phase I stage
Figure 41: Orphan diseases deal royalty rate distribution, US$million - phase II stage
Figure 42: Orphan diseases deal royalty rate distribution, US$million - phase III stage
Figure 43: Orphan diseases deal royalty rate distribution, US$million - regulatory stage
Figure 44: Orphan diseases deal royalty rate distribution, US$million - marketed stage
Figure 45: Summary median royalty rate by stage of development, 2009-2014
Figure 46: Top orphan diseases deals by value since 2009
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Read the full report:
Orphan Diseases Partnering Terms and Agreements

https://www.reportbuyer.com/product/2043441/Orphan-Diseases-Partnering-Terms-and-Agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
15th Cloud Expo, which took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the conference content of @ThingsExpo, Big Data Expo, and DevOps Summit to include two developer events. IBM held a Bluemix Developer Playground on November 5 and ElasticBox held a Hackathon on November 6. Both events took place on the expo floor. The Bluemix Developer Playground, for developers of all levels, highlighted the ease of use of Bluemix, its services and functionalit...
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happe...
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone far and beyond the capabilities of "traditional" system-level monitoring tools and approaches and requires much broader knowledge of business and applications as a whole. The goal of DevOps is to connect all aspects of app...
When an enterprise builds a hybrid IaaS cloud connecting its data center to one or more public clouds, security is often a major topic along with the other challenges involved. Security is closely intertwined with the networking choices made for the hybrid cloud. Traditional networking approaches for building a hybrid cloud try to kludge together the enterprise infrastructure with the public cloud. Consequently this approach requires risky, deep "surgery" including changes to firewalls, subnets...
Want to enable self-service provisioning of application environments in minutes that mirror production? Can you automatically provide rich data with code-level detail back to the developers when issues occur in production? In his session at DevOps Summit, David Tesar, Microsoft Technical Evangelist on Microsoft Azure and DevOps, will discuss how to accomplish this and more utilizing technologies such as Microsoft Azure, Visual Studio online, and Application Insights in this demo-heavy session.
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's large...
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges. In his session at @ThingsExpo, Jeff Kaplan, Managing Director of THINKstrateg...
SYS-CON Media announced that Centrify, a provider of unified identity management across cloud, mobile and data center environments that delivers single sign-on (SSO) for users and a simplified identity infrastructure for IT, has launched an ad campaign on Cloud Computing Journal. The ads focus on security: how an organization can successfully control privilege for all of the organization’s identities to mitigate identity-related risk without slowing down the business, and how Centrify provides ...
"We help companies that are using a lot of Software as a Service. We help companies manage and gain visibility into what people are using inside the company and decide to secure them or use standards to lock down or to embrace the adoption of SaaS inside the company," explained Scott Kriz, Co-founder and CEO of Bitium, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
"SAP had made a big transition into the cloud as we believe it has significant value for our customers, drives innovation and is easy to consume. When you look at the SAP portfolio, SAP HANA is the underlying platform and it powers all of our platforms and all of our analytics," explained Thorsten Leiduck, VP ISVs & Digital Commerce at SAP, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.